Bonipharmex AB

Active
559031-6062Limited company (AB)Registered 2015TÄBY

Key figures

5 034 000 kr−16,6%
Revenue 2025
+47,5%
Average annual growth 2017/18–2025
02 m4 m6 m8 m2017/182018/19202020212022202320242025

Key figures

2025

Summary: Bonipharmex AB

What kind of company is it?

Bonipharmex AB (org. no. 559031-6062) is a limited company (AB). The company was registered in 2015 and has existed for 11 years. Registered seat: Täby. Industry according to Statistics Sweden: wholesale of pharmaceutical and medical goods (SNI 46460).

How is the company doing financially?

Net sales in financial year 2025 were 5 034 000 kr, down 16,6 % on the previous year (6 036 000 kr). From 2018 to 2025, net sales grew by an average of 47,5 % per year. Net profit for 2025 was 17 830 kr (0,4 % of net sales). The company was profitable in 7 of the 8 reported financial years. Employees in financial year 2024: 1. Net sales per employee were 6 036 000 kr. At the end of financial year 2025, total assets were 9 556 639 kr and equity 117 492 kr (equity ratio 1,2 %).

Where does the data come from and how up to date is it?

Company details and digitally filed annual reports come from the open data of the Swedish Companies Registration Office (Bolagsverket) and the industry code from Statistics Sweden (CC BY 2.5 SE); bolagsprofil.se updates them daily. The latest annual report is signed by 2 people. Data as of 2026-11-16. Changes, averages and ratios are calculated by bolagsprofil.se from open data and are not an official assessment.

Summary of annual reports2018–2025
20212022202320242025
Sales revenue960 0002 352 0002 976 0006 036 0005 034 000
Profit for the reporting year1 286−28 15427 6237 94817 830
Retained earnings of previous periods—————
Total assets1 001 9141 739 0984 031 0497 142 8819 556 639
Total liabilities945 1701 710 5083 974 8367 043 2209 439 147
Total equity56 74428 59056 21399 661117 492
Employees1111—
Proposed dividend—0000

A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.